Research Gaps and Future Directions in GLP-1, Cancer Studies Most clinical evidence pertains to cancer incidence rather than progression, and the review calls for additional trials specifically in patients undergoing cancer treatment or in remission
However, potency does decline gradually over time
Call us or book online to get your consultation scheduled in Johnson City
The underreported symptoms are leads that came from patients themselves, unprompted, and clinicians could potentially pay attention to them. Although the study is not representative of the broader populationReddit users are generally younger, more likely male and based in the U.S.the symptoms reported collectively match known side effects of semaglutide and tirzepatide
The main risk is digestive discomfortbloating, mild constipationespecially if youre not used to a concentrated gelatin dose
One area gaining attention is the use of GLP-1 (glucagon-like peptide-1) receptor agonists